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Abstract
Attenuated yellow fever (YF) virus 17D/17DD vaccines are the only available protection
from YF infection, which remains a significant source of morbidity and mortality in the tropi-
cal areas of the world. The attenuated YF virus vaccine, which is used worldwide, generates
both long-lasting neutralizing antibodies and strong T-cell responses. However, on rare oc-
casions, this vaccine has toxic side effects that can be fatal. This study presents the design
of two non-viral DNA-based antigen formulations and the characterization of their expres-
sion and immunological properties. The two antigen formulations consist of DNA encoding
the full-length envelope protein (p/YFE) or the full-length envelope protein fused to the lyso-
somal-associated membrane protein signal, LAMP-1 (pL/YFE), aimed at diverting antigen
processing/presentation through the major histocompatibility complex II precursor compart-
ments. The immune responses triggered by these formulations were evaluated in H2b and
H2d backgrounds, corresponding to the C57Bl/6 and BALB/c mice strains, respectively.
Both DNA constructs were able to induce very strong T-cell responses of similar magnitude
against almost all epitopes that are also generated by the YF 17DD vaccine. The pL/YFE
formulation performed best overall. In addition to the T-cell response, it was also able to
stimulate high titers of anti-YF neutralizing antibodies comparable to the levels elicited by
the 17DD vaccine. More importantly, the pL/YFE vaccine conferred 100% protection
against the YF virus in intracerebrally challenged mice. These results indicate that pL/YFE
DNA is an excellent vaccine candidate and should be considered for further developmental
studies.
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Author Summary
DNA and other nucleic acid vaccine technologies are advancing quickly, and new potent
delivery methods are demonstrating great potential in human clinical trials. In this manu-
script, we report a highly protective DNA vaccine against the yellow fever virus. This vac-
cine was engineered with a molecular adjuvant technology to enhance the exposure of the
vaccine antigens to the immune system, resulting in augmented CD4+ helper responses.
We postulate that the robust CD4+ responses help the B cells and the CD8+ cells mature
more efficiently and produce better antibodies and cytotoxic cells, respectively. Our results
show that vaccination with this yellow fever DNA formulation elicited protective levels of
neutralizing antibodies and very strong cellular responses at similar levels to the responses
elicited by the live attenuated 17DD vaccine. In addition, these results also suggest a very
important role for cellular responses in mediating protection against yellow fever virus.
The results reported here are very promising and further studies may lead to a new yellow
fever vaccine for human use.
Introduction
The yellow fever (YF) virus is considered the prototype member of the family Flaviviridae,
which includes several other viruses of medical importance, such as the dengue, Japanese en-
cephalitis, tick-borne encephalitis and West Nile viruses [1]. According to the World Health
Organization (WHO), more than 200,000 cases of YF infection, including 30,000 deaths, occur
annually, with 90% of cases occurring in Africa [2]. The safest strategy for preventing YF infec-
tion is still vaccination because there is currently no drug that is effective against YF virus infec-
tion. In the last 70 years, more than 500 million people around the world have been vaccinated
with the YF 17D/17DD virus-attenuated vaccines with a remarkable record of safety and effica-
cy [3]. Attenuated YF virus vaccines generate both long-lasting neutralizing antibodies and T-
cell responses [4, 5]. However, despite several improvements in the manufacturing process and
quality control, severe side-effects resulting from vaccination continue to be reported [6–9]. In
some cases, vaccination was associated with increased severity of symptoms [10] and on rare
occasions with fatal reactions [11, 12]. In view of this, the development of alternative vaccina-
tion strategies, such as DNA-based vaccines encoding specific virus sequences, has been con-
sidered [13–16].
The YF virus genome consists of a single-stranded, positive-sense RNA molecule of ~10.8
kb, flanked by a 5’ cap and a 3’ non-polyadenylated terminal loop structure. It expresses three
genes for structural proteins (capsid—C, pre-membrane/membrane—pM/M, and envelope—
E) and seven genes that code for non-structural (NS) proteins (NS1, NS2a, NS2b, NS3, NS4a,
NS4b, and NS5). Coexpression of flavivirus M and E genes in mammalian cells has been dem-
onstrated to produce virus-like particles (VLPs) containing pM/M and E proteins [17–19]. The
E protein is known to be the principal virus surface protein and the main target for neutralizing
antibodies. pM/M and E coexpression, as a vaccination strategy, has been described as a way of
triggering neutralizing antibodies against the Japanese encephalitis [19–21], West Nile [22]
and dengue viruses [17,18,23,24].
DNA vaccines express endogenous cytoplasmic antigens, which are mostly introduced to
the immune system through the major histocompatibility complex (MHC) class I molecules
that are mostly associated with cellular cytotoxic responses and often fail to elicit a satisfactory
humoral response, which is essential for efficient virus neutralization. Activation of CD4+ help-
er cells is important for the development of CD8+ responses, immunological memory [25],
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antibody maturation, class switching and expansion of antigen-specific B cells [26]. Several
strategies have been proposed for enhancing MHC class II presentation of antigens encoded by
DNA vaccines. The targeting of the MHC II compartment with other flavivirus E antigens has
been shown to enhance neutralizing antibody production in immunized mice [17, 22, 24] and
in non-human primates (Raviprakash personal communication at 2004 ASTMHmeeting,
http://www.astmh.org/meeting_archives.htm).
One of the main strategies for targeting the MHC II compartment with DNA-encoded anti-
gens is based on the expression of the antigen fused to the lysosomal-associated membrane
protein 1 (LAMP-1), a protein primarily found in the outer membrane of lysosomes [27]. The
chimeric antigens expressed by DNA formulations in the context of type I trans-membrane
LAMP are directed to compartments rich in MHC II, called the MHC II compartment (MIIC),
which is where the peptide-MHC II complexes are formed [28, 29]. Other LAMP/antigen chi-
meric strategies, such as LAMP/HIV Gag [25, 26, 30, 31] and LAMP/dengue virus 2 pM/M-E
[17, 24] antigens, have been shown to target the MIIC and were found to elicit enhanced im-
mune responses compared with vaccines encoding unmodified native antigens.
This study investigated T-cell and humoral immune responses to the envelope of YF virus
in C57Bl/6 and BALB/c mice immunized with DNA formulations expressing the full-length
YF envelope protein, either as a wild-type or fused to LAMP. Responses in the mice were com-
pared with the results obtained with standard immunization using the YF 17DD vaccine. We
also evaluated the ability of DNA vaccines to provide protection against a lethal challenge. We
show that although the YF 17DD vaccine produced higher neutralizing antibody titers, both
DNA vaccine constructs encoding the entire E protein were also able to protect the mice
against lethal challenge.
Materials and Methods
Yellow fever vaccine, cells and antibodies
The attenuated 17DD human yellow fever vaccine was obtained from Bio-Manguinhos, a unit
of the Oswaldo Cruz Foundation (FIOCRUZ, Rio de Janeiro, Brazil). The vaccine was reconsti-
tuted in chilled PBS, kept in an ice bath, and used for mouse immunizations within 4 hours of
reconstitution. VERO and 293 cells were obtained from the ATCC (Rockville, MD, USA) and
were grown according to the supplier’s instructions in a DMEMmedium (Invitrogen) contain-
ing 10% fetal bovine serum (Gibco), 1% penicillin/streptomycin (Gibco) and 1% L-glutamine
(Sigma). YF virus strain 17DD was propagated in Vero cells at 37°C in 5% CO2 to a titer of 10
6
plaque-forming units (PFUs) per ml. The polyclonal anti-YF hyperimmune serum used in
immunofluorescence assays was obtained from mice immunized with the YF 17DD virus-at-
tenuated vaccine in our laboratory. Secondary antibodies were purchased either from Jackson
Immunoresearch Laboratories (Bar Harbor, ME, USA) or Molecular Probes (Seattle, WA,
USA).
Peptides
A set of 120 peptides of 15 amino acids each (15-mers), overlapping by 11 amino acids (15x11)
and comprising the entire length of the envelope protein of the YF 17DD virus (NCBI Gen-
Bank accession number U17066), was synthesized using Schafer-N (Copenhagen, Denmark).
The peptides were HPLC-purified to 80% purity or greater, with the exception of a few peptides
that could not be purified and were used as crude extracts. The identity of each peptide was
confirmed via mass spectrometry, and the amount of purified peptide was precisely measured.
Stock solutions of all peptides were prepared via dilution in water when possible, or in a solu-
tion of 10 to 100% DMSO, to a final concentration of 20 mg/mL and were stored at −20°C. For
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the ELISPOT assays, the peptides were used at a 10 μg/mL final concentration. The highest
DMSO concentration in the ELISPOT experiments was 0.05%.
DNA constructs
The full YF genome, used as template to design primers for p/YFE and pL/YFE amplification,
is deposited in NCBI’s GenBank under accession number NC 002031. The Kyte-Doolittle hy-
dropathy plot analyzed this sequence to identify the capsid ER translocation signal and the pre-
dicted envelope trans-membrane domain of the YF genome. The wild-type pM/M-E amplicon
starts with the ER capsid signal and ends with the envelope trans-membrane domain. To gen-
erate the pL/YFE construct, we designed a reverse primer that hybridizes to the YF genome just
upstream of the envelope trans-membrane domain to replace it with the human membrane an-
chor and cytoplasmic domains of LAMP (Fig 1). The DNA pM/M-E sequence was amplified
from the YF 17DD infectious clone using specific primers that incorporated an ATG start site
in the context of the Kozak sequence and a translational stop codon. PCR amplification was
Fig 1. p/YFE and pL/YFE DNA vaccine construct design. The fragment pM/M-E (extending from nucleotides 392 to 2452, black arrows) was amplified
using PCR and cloned into a p43.2 vector to generate the p/YFE vector. This construct starts with the ER capsid signal and ends with the envelope trans-
membrane domain. To generate the pL/YFE construct, we designed a second forward primer that annealed just upstream of the envelope trans-membrane
domain to amplify the fragment extending from nucleotides 392 to 2323. This fragment was fused to the C-terminal end of LAMP and cloned into the
same vector.
doi:10.1371/journal.pntd.0003693.g001
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performed using the proofreading TGO DNA polymerase (Roche, Indianapolis, IN, USA) and
0.6 μM of each primer. The amplicon was inserted into the p43.2 vector between the XhoI and
NotI cleavage sites to generate the p/YFE construct. The pL/YFE construct, however, was ob-
tained in two steps. First, the pM/M-E sequence was amplified using a reverse primer that hy-
bridized upstream of the trans-membrane domain of the YF envelope protein. Then, the PCR
product was inserted into the p43.2 vector between the NheI and XhoI sites, generating an in-
termediate construct (p/YFEINT), ready to receive the membrane anchor and cytoplasmic do-
mains of LAMP. Second, LAMP was amplified from the p43.2-Gag/LAMP vector and was
inserted into p/YFEINT, between the XhoI and XbaI sites, to generate the pL/YFE construct.
Both the p/YFE and pL/YFE constructs were checked by sequencing; among the 2,061 nucleo-
tides of the pM/M-E wild-type construction (p/YFE) that encodes 687 amino acids, two nonsy-
nonymous mutations were found. An alanine (A) was replaced with a valine (V) at position
250, and a serine (S) was replaced with an aspartic acid (D) at position 349. Given that both
mutations were also found at the same locations in the 644-residue sequence of the pL/YFE
construction, they are very likely present in the YF 17DD infectious clone that was used as a
DNA template. Regardless of the source of the two mutations, both mutations were deemed to
be irrelevant for our vaccine studies as the E protein has several B-cell and T-cell preserved epi-
topes distributed along its sequence.
Transfections, western blotting and fluorescence assays
293 cells were plated onto cover slips and transfected with p/YFE, pL/YFE or empty p43.2 vec-
tors, using Lipofectamine 2000 (Invitrogen Life Technologies). For Western blotting, transfec-
tions were carried out in 6-well tissue culture plates with 10 μg of each plasmid and 40 μl of
Lipofectamine 2000, whereas transfections for fluorescence assays were carried out in 24-well
tissue culture plates with 2.5 μg of each plasmid and 10 μl of Lipofectamine 2000, both in accor-
dance with the manufacturer’s instructions. Vero cell extracts infected with the YF 17DD virus
strain were used as a positive control. After 48 hours, both transfected and infected cell extracts
were processed.
For Western blot analysis, cell extracts were resuspended in 2x Laemmli denaturing protein
sample buffer, fractionated in 12.5% SDS-PAGE and transferred to a polyvinylidene difluoride
(PVDF) membrane. After blocking with 5% milk/0.05% PBS-Tween 20, membranes were incu-
bated for 1 hour with the appropriate primary polyclonal antibodies (anti-YFV hyperimmune
rabbit serum, previously produced in our laboratory) diluted 1:500 in 1% milk/0.1%
PBS-Tween 20. Membranes were washed 3 times with 1x PBS for 10 minutes/wash and incu-
bated for 1 hour with 1:5,000 goat anti-rabbit IgG antibody conjugated with horseradish perox-
idase (Jackson Immunoresearch Laboratories). The Western blot reactions were detected using
enhanced chemiluminescence (ECL) reactions (Millipore). For fluorescence assays, cell extracts
were fixed in 100% methanol at—20°C for 5 minutes, blocked with 1% BSA/PBS solution for
30 minutes, and incubated with an anti-YFV hyperimmune mouse antibody diluted 1:200 for 1
hour, followed by a 1-hour incubation with secondary antibody diluted 1:500 (Alexa 488-con-
jugated goat anti-mouse, Molecular Probes, Seattle, WA, USA). The cover slips were then
mounted on glass slides using ProLong Gold (Molecular Probes, Seattle, WA, USA) and ob-
served through a confocal microscope. The images were acquired using a Leica SPII-AOBS
confocal microscope (Leica Microsystem, Hm) with a 63× oil immersion objective NA 1.3. The
Alexa 488 fluorochrome was excited using an ArKr laser at 488 nm. The digital image was ac-
quired using Leica software in a 24-bit RGB format with a 1024 × 1024 pixel area. Fields were
chosen for imaging based on the spread and morphology of the cells.
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Immunological assays
Female BALB/c (H2d) and C57Bl/6 mice (H2b), aged 6 to 8 weeks (Charles River, Kingston,
NY, USA), were used for the ELISPOT assays. They were housed in micro-isolator cages under
specific pathogen-free conditions and handled in accordance with the Johns Hopkins Institu-
tional Animal Care and Use Committee (IACUC) protocol number MO05M336. The animals
were immunized at days zero and 21 and used for the experiments seven to ten days after the
last immunization. For the neutralization and protection assays, three-week-old female BALB/
c and C57Bl/6 mice were obtained from the Oswaldo Cruz Foundation Breeding Center (Rio
de Janeiro, Brazil) and were housed at the Experimental Animal Laboratory (Oswaldo Cruz
Foundation, Rio de Janeiro, Brazil) under specific pathogen-free conditions and handled in ac-
cordance with the Oswaldo Cruz Foundation Commission for Ethical Animal Use (CEAU)
protocol number P0112-02. The animals were immunized at days zero, 30 and 45, and sera
were collected via a cut in the tail vein a day before every immunization. For both protocols,
the animals were immunized subcutaneously at the base of the tail with either the YF 17DD
vaccine at 104 PFUs/50 μl, the DNA constructs at 50 μg/50 μl, or 50 μl of PBS as a negative
control.
ELISPOT assays were performed to quantify IFN-gamma spot-forming cells (SFCs) gener-
ated via DNA construct immunization. Seven to 10 days after the last immunization, the mice
were sacrificed and their spleens were removed. Splenocytes were isolated using standard
methods, and single-cell suspensions, depleted of red blood cells, were prepared from freshly
isolated splenocytes in culture medium (RPMI 1640 medium supplemented with 10% v/v fetal
bovine serum, 100 units/ml penicillin/streptomycin, 2 mM L-glutamine, 50 μM 2-mercap-
toethanol and 1 MHEPES buffer). IFN-gamma ELISPOT assays were performed in accordance
with the manufacturer’s instructions (BD-Biosciences, San Diego, CA, USA). First, the ELI-
SPOT plates were coated with anti-IFN-gamma antibody at 5 μg/ml and incubated at 4°C over-
night. The plates were blocked with RPMI 1640 medium containing 10% FBS for 2 h at room
temperature, and total splenocytes (1×106 cells/well) from immunized mice were then added.
The cells were cultured at 37°C in 5% CO2 with culture medium alone (RPMI 1640 medium
supplemented with 5% v/v fetal calf serum, 100 units/ml penicillin/streptomycin, and 2 mM L-
glutamine) or with culture medium in the presence of concanavalin A (2.5 μg/ml; Sigma), 109
PFUs/mL of inactivated YF virus as a positive control (strain 17DD), or individual 15-mers
from the envelope protein of the YF 17DD virus at 1 μg/ml. After 16 h of culture, the plates
were washed and incubated with biotinylated anti-IFN-gamma for 2 h at room temperature,
followed by HRP-conjugated avidin for 1 h at room temperature. Reactions were developed
with AEC substrate (Calbiochem-Novabiochem Corporation, San Diego, CA, USA). The quan-
tification of spot-forming cells (SFCs) was carried out using the Immunospot Series Analyzer
ELISPOT reader (Cellular Technologies Ltd (CTL), Shaker Heights, OH, USA) with the aid of
Immunospot software 3.0 (Cellular Technologies Ltd). The data are represented as the number
of SFCs/106. The results were considered positive if the number of SFCs was greater than 20
and higher than the background (culture with medium alone) plus three standard deviations.
The results are presented after subtraction of the background.
Viral neutralization assays
Plaque reduction neutralization tests (PRNT) were carried out using VERO cells seeded at a
density of 62,500 cells/cm2 in 96-well microplates, as previously described [32]. The PRNT
tests for the detection of anti-YF nAb were performed after two-fold serial dilutions of serum
(1/5 to 1/640) on microtiter plates and incubation with 30 PFUs of the YF 17DD challenge
virus strain in each well. After incubation at 37°C in a 5% CO2 atmosphere for 1 h, 50 μl of
Protective DNA Yellow Fever Virus Vaccine
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Vero cell suspensions (4×104/well) in medium 199 (Invitrogen) was added, and the plates were
incubated at 37°C for 3 h. The medium was then discarded and the cells were overlaid with
100 μl of medium containing 3.5% carboxymethylcellulose. After 6–7 days of incubation at
37°C in 5% CO2, cell monolayers were fixed with formalin and stained with crystal violet so
plaques could be counted. Standard sera of known antibody content in terms of International
Units (IU) were included in each set of tests. The log10 dilution of the test and standard sera,
which reduced the plaque numbers by 50% relative to the virus control, were determined via
interpolation. The mean antibody content at the 50% end point of the standard was then calcu-
lated and added to the log10 end point for each sample to give log10 mIU/ml. Plaque neutraliza-
tion titers were calculated as the highest dilution of antibody able to reduce 50% of the plaques
from input virus. The lower limit of detection of the assay was 84.5 mIU/mL.
Protection assays and statistical analysis
Groups of three-week-old BALB/c and C57Bl/6 mice immunized three times with either the
YF 17DD vaccine or the DNA constructs were inoculated intra-cerebrally with 30 μl of M199
medium containing 105 PFUs of the YF 17DD virus 15 days after the last immunization. The
animals were monitored for 21 days and deaths were recorded. Moribund animals were sacri-
ficed by exposure to CO2.
Comparisons between ELISPOT and neutralization assay results were made using an un-
paired T-test. The mean survival times in each group of mice were compared using a one-way
analysis of variance (ANOVA) and the Kruskal-Wallis non-parametric test. Statistical tests and
graphs were performed and produced using GraphPad Prism version 4.0 (GraphPad Software,
San Diego, CA, USA; www.graphpad.com).
Results
The p/YFE and pL/YFE DNA constructs express yellow fever proteins in
293 cells
293 cells were transfected with the p/YFE and pL/YFE expression vectors encoding the pM/
M-E and pM/M-E/LAMP proteins, respectively. Validation of plasmid protein expression and
cellular steady-state localization was carried out using Western blot and immunofluorescence
analyses. Both the E and E/LAMP proteins were stained using polyclonal anti-YF hyperim-
mune serum. Western blotting detected specific bands for the E (p/YFE) and E/LAMP (pL/
YFE) proteins, as well as the wild-type (YF virus) E protein (Fig 2). Immunofluorescence assays
showed the characteristic reticular membrane distribution (associated with the typical cellular
trafficking of the viral envelope protein) in p/YFE-transfected 293 cells expressing the wild-
type E protein (Fig 3A). By contrast, the E/LAMP chimeric protein from pL/YFE-transfected
cells showed the typical punctuated lysosomal-like distribution of endogenous LAMP (Fig 3B).
The figure represents several independent assays where the expression and cellular steady-state
localization of both the E and E/LAMP proteins were considered to be invariable.
Characterization of the cellular response triggered by 17DD vaccination
in C57Bl/6 mice
It is known that some mouse strains with distinct genetic backgrounds, when exposed to the
same antigens, can polarize towards T-helper-1 (Th1) or T-helper-2 (Th2) responses. Some
strains are more prone to produce Th1 responses, whereas others are more prone to polarize
towards Th2. BALB/c and C57Bl/6 mice strains have been known to produce this type of dis-
tinct T-helper responses in several models and, thus, we selected these two strains to investigate
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how they would respond to our vaccines. An optimized YF 17DD vaccine immunization proto-
col and IFN-gamma ELISPOT assay conditions, which were previously described for BALB/c
(H2d: Dd, Kd, Ld, I-Ad, and I-Ed) mice [33], were used to characterize the T-cell responses to
peptides of the YF 17DD virus proteins in C57Bl/6 (H2b: Db, Kb and I-Ab) mice. The first
round of experiments with total splenocytes led to the identification of 11 antigenic 15-mer
peptides from the YF envelope protein. The subsequent experiments were performed using
splenocytes depleted of CD4+ or CD8+ lymphocytes, which lead to the identification of epi-
topes presented by MHC class I or II, respectively. The depletion typically removed>95% of
the targeted population, as assessed via flow cytometry. The CD4-depleted splenocytes, which
correspond to the CD8+ lymphocyte response, reacted to seven peptides, whereas the CD8-de-
pleted splenocytes, which correspond to the CD4+ lymphocyte response, were able to respond
Fig 2. p/YFE and pL/YFE DNA vaccine expression analysis via Western blotting. 293 cells were
transfected with the p/YFE or pL/YFE DNA construct and incubated for 48 hours prior to total protein sample
preparation. The p43.2 empty vector was used as a negative control, and cells infected with the YF 17DD
virus strain were used as a positive control. Cell extracts were transferred to the PVDFmembrane and
incubated with anti-YFV hyperimmune antibody, followed by incubation with a secondary antibody
conjugated with horseradish peroxidase that was revealed using an enhanced chemiluminescence (ECL)
reaction. Both the E- and E-LAMP-encoded antigens were successfully expressed and were each the
appropriate molecular size.
doi:10.1371/journal.pntd.0003693.g002
Fig 3. p/YFE and pL/YFE DNA vaccine intracellular steady-state localization analysis using
immunofluorescence assays. 293 cells were transfected with the p/YFE or pL/YFE DNA construct and
incubated for 48 hours prior to methanol fixation. The p43.2 empty vector was used as a negative control, and
cells infected with the YF 17DD virus strain were used as a positive control. Fixed cells were incubated with
anti-YFV hyperimmune antibody, followed by incubation with a secondary antibody conjugated with Alexa
Fluor-488 dye for microscopic analyses. The characteristic reticular membrane distribution of the viral
envelope protein was detected in the p/YFE-transfected cell expressing the wild-type E protein (A), whereas
the E/LAMP chimeric protein expressed by the pL/YFE-transfected cells showed the typical punctuated
lysosomal-like distribution of endogenous LAMP (B).
doi:10.1371/journal.pntd.0003693.g003
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to five 15-mer peptides (Table 1). The results of quantitative (IFN-gamma SFCs/106) epitope
mapping for the YF envelope protein in 17 DD immunized C57Bl/6 mice are shown in
Table 2. Splenocytes from naïve animals did not react to any of the peptides tested.
p/YFE and pL/YFE DNA immunizations in C57Bl/6 (H2b) and BALB/c
(H2d) mice elicit T-cell responses of similar magnitude and against the
same repertoire of epitopes induced by the YF 17DD vaccine
The T-cell responses of H2b and H2d mouse strains induced by immunization with the p/YFE
and pL/YFE plasmids were evaluated, and the results were compared with the responses ob-
served for the YF 17DD vaccine immunization. Immunization with the p/YFE or pL/YFE plas-
mids generated a vigorous T-cell response in C57Bl/6 mice. Both plasmids, in addition to
bringing about a T-cell response pattern similar to that produced by the YF 17DD vaccine,
were able to elicit a significantly higher number of IFN-gamma SFCs (>200 IFN-gamma SFCs/
106 splenocytes) for many immunogenic peptides of the YF envelope protein (Table 3;
p<0.05) than was immunization with the attenuated virus vaccine.
Interestingly, p/YFE was able to generate a considerable response to the E413–427 and E417–
431 peptides, which were not present after YF 17DD immunization and were very scarce after
pL/YFE immunization (Table 3). Remarkably. p/YFE also brought about a stronger response
to peptide E1–15 than both the YF 17DD and pL/YFE vaccines.
In BALB/c immunized mice, both the p/YFE and pL/YFE DNA constructs generated an im-
mune response very similar to that obtained with the YF 17DD vaccine, eliciting almost the
same immunogenic determinants (Table 3). The only considerable exception was the lack of
response in YF-17DD-immunized mice to peptide E329–343, which contains a previously char-
acterized MHC class I epitope (CD8+ response) (Table 4). Both the p/YFE and pL/YFE plas-
mids also produced a significantly higher number of T cells specific to the immunodominant
E57–71 and E61–75 peptides (p<0.05), which contain MHC class I and class II epitopes for the
H2d mouse strain. The number of IFN-gamma SFCs was similar for all remaining positive pep-
tides. Groups of mice from both strains immunized with either the empty plasmid or a plasmid
expressing only the LAMP protein did not react to any of the peptides tested.
Table 1. Position and restriction of the YF envelope epitopes in YF-17DD-immunized C57Bl/6 (H2b) mice.
YF envelope peptide position Peptide sequence Restriction
E1-15 AHCIGITDRDFIEGV CD8
E201-215 ESWIVDRQWAQDLTL CD4
E229-243 HHLVEFEPPHAATIR CD4
E233-247 EFEPPHAATIRVLAL CD4
E345-359 NKGILVTVNPIASTN CD4/CD8
E349-363 LVTVNPIASTNDDEV CD4
E353-367 NPIASTNDDEVLIEV CD8
E465-479 GINTRNMTMSMSMIL CD4
E473-487 MSMSMILVGVIMMFL CD4
E477-491 MILVGVIMMFLSLGV CD8
E481-493 GVIMMFLSLGVGA CD8
doi:10.1371/journal.pntd.0003693.t001
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Evaluation of the humoral responses generated by the YF 17DD and the
DNA construct immunizations
The protection provided by the YF vaccine is mainly attributed to the neutralizing antibody
(nAb) response generated after vaccination. Because the presence of nAb is a hallmark of pro-
tection, we evaluated the humoral response of C57Bl/6 and BALB/c mice after immunization
with the DNA constructs and compared them with the levels of nAb obtained after immuniza-
tion with the YF 17DD vaccine. To investigate the kinetics of nAb responses, the animals were
immunized at days zero, 30 and 45 and bled 15 days after each immunization.
The YF 17DD vaccine was able to produce very high levels of nAb in C57Bl/6 and BALB/c
mice after the first immunization (day 15). nAb levels in C57Bl/6 mice seemed to reached a pla-
teau after the second immunization (day 45) and increased slightly after the third immuniza-
tion (day 60), whereas BALB/c mice showed increasing levels of nAb after the second (day 45)
and third (day 60) immunization with the YF 17DD vaccine. The levels of nAb observed in
C57Bl/6 mice (9,664.0 mIU/mL; obtained at the highest dilution tested) were approximately
20% higher compared with the levels observed in BALB/c mice (7,500±780.1 mIU/mL) (Fig 4).
In C57Bl/6 mice, both plasmids expressing the whole envelope protein (p/YFE and pL/YFE)
were able to produce significant levels of nAb (p<0.0039 and p<0.002, respectively) after three
immunizations compared with the empty vector control. The DNA plasmid pL/YFE, express-
ing the chimeric E-LAMP protein, led the BALB/c mice to produce higher titers of nAb after
the second immunization compared to the p/YFE plasmid. The levels of nAb titers increased
after the third immunization and were significantly higher (p<0.045) than those of the control
groups immunized with empty vector or PBS (Fig 4).
On average, the pL/YFE DNA immunization elicited nAb titers 7-fold greater than the p/
YFE DNA immunization. Compared with the 17DD attenuated virus vaccine, the nAb titers
produced by the pL/YFE DNA vaccine were approximately 3.5-fold lower. The fact that these
DNA vaccines produced these levels of nAb may still be considered significant.
Table 2. Characterization of the cellular responses produced by 17DD vaccination in C57Bl/6 mice.
T-cell responses of C57Bl/6 (H2b) mice
# of IFN-γ SFCs/106 splenocytes YF envelope 15-mer peptides
Total splenocytes CD8-depleted cells CD4-depleted cells
<100 1–15 201–215 353–367
201–215 345–359 477–491
335–367 349–363 481–493
345–359 473–487
349–363
473–487
477–491
481–493
100–200 229–243 229–243 1–15
465–479 465–479
>200 233–247 233–247 345–359
C57Bl/6 mice were immunized on day 0 and boosted on day 21 with 104 PFUs of the human YF 17DD vaccine, and the splenocytes were tested in IFN-γ
ELISPOT assays 7–10 days after the boost. The peptides used for the in vitro stimulation were 15-mers overlapping by 11 amino acids and comprising
the entire length of the YF envelope protein. The total splenocyte, CD8-depleted splenocyte and CD4-depleted splenocyte populations were analyzed.
The SFC values represents the average of two to four experiments performed with pools of three to five mice each.
doi:10.1371/journal.pntd.0003693.t002
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Protection evaluation via challenge
Intra-cerebral challenge with the YF 17DD virus in mice is a useful model for evaluating the
protection provided by vaccine candidates [34]. We evaluated our DNA constructs using the
immunization/challenge model by injecting 105 PFUs of the YF 17DD virus intra-cerebrally
into DNA-immunized C57Bl/6 and BALB/c mice. The animals were immunized three times at
days 0, 30 and 45 and were challenged 15 days after the last immunization. As previously re-
ported [35], immunization with YF 17DD vaccine was able to protect both C57Bl/6 and BALB/
c mouse strains against the intra-cerebral challenge. In a similar fashion, immunization with
both DNA constructs expressing the full-length YF envelope protein was able to fully protect
both mouse strains from the lethal challenge. The majority of mice immunized with PBS or
empty vector died 10 to 14 days after the challenge assay (Table 5 and Fig 5).
Table 3. Comparison of the C57Bl/6 and BALB/c T-cell responses produced by immunization with p/YFE, pL/YFE and the YF 17DD vaccine.
C57Bl/6 (H2b) BALB/c (H2d)
# of IFN-γ
SFCs/106
splenocytes
YF envelope
15-mer peptides
(10 μg/mL)
# of IFN-γ
SFCs/106
splenocytes
YF envelope
15-mer peptides
(10 μg/mL)
YF 17DD
vaccine
p/YFE pL/YFE YF 17DD
vaccine
p/YFE pL/YFE
<200 1–15 5–19 169–183 <200 25–39 65–79 21–35
201–215 169–183 201–215 129–143 129–143 25–39
229–243 201–215 349–363 133–147 137–151 129–143
233–247 225–239 385–389 157–171 201–215 201–215
345–359 317–331 413–427 201–215 213–227 213–227
349–363 345–359 417–431 213–227 233–247 233–247
465–479 349–363 473–487 221–235 237–251 237–251
473–487 353–367 233–247 425–439 437–451
477–491 385–389 237–251 437–451 465–479
329–343 461–475 477–491
425–439 461–475
437–451 465–479
465–479 473–487
473–487 477–491
477–491
200–400 229–243 1–15 200–400 61–75 133–147 61–75
417–431 229–243 133–147
473–487 233–247
465–479 345–359
465–479
401–600 233–247 401–600 57–71 57–71
413–427 61–75
>600 1–15 >600 57–71
C57Bl/6 and BALB/c mice were immunized on day 0 and boosted on day 21 with 104 PFUs of the human YF 17DD vaccine or with 50 μg of either p/YFE
or pL/YFE. Total splenocytes were harvested 7–10 days after the last immunization and assayed in vitro using an IFN-γ ELISPOT assay with 15-mers
overlapping by 11 amino acids and comprising the entire length of the YF envelope protein. The SFC values represent the average of two to four
experiments performed with pools of three to five mice each (p<0.05).
doi:10.1371/journal.pntd.0003693.t003
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Discussion
YF infection continues to be a worldwide problem, especially in tropical areas [11], but this
may change as the world continues to be affected by climate change. Despite the high efficiency
of commercially available YF vaccines, 17D and 17DD, there are a few reports of rare but fatal
side-effects after vaccination [9, 11, 12]. Furthermore, these vaccines are not recommended for
infants, pregnant women, immunodeficient subjects, or those allergic to the egg components
present in the vaccine formulations [36]. In light of these factors, there is reason to pursue
complementary or alternative YF vaccine strategies that could replace the use of the virus-at-
tenuated vaccine version.
Although no DNA vaccines have yet been approved for human use, they represent potential
candidates to replace live/attenuated vaccine formulations because they are considered safer.
DNA formulations can be easily manipulated, do not require a cold-chain for distribution and
eliminate the infectious nature of live/attenuated agents. They also allow the manipulation of
immunogens to provide the immune system with the desired epitopes and signals while avoid-
ing the use of unnecessary or potentially harmful antigens or epitopes [37, 38].
Previous studies have described the development of DNA vaccines against flaviviruses
based on the expression of the pM/M-E virus sequence cloned in-frame with the LAMP se-
quence [17, 22, 24]. This approach showed that the chimeric protein, driven by the cytoplasmic
sequence of LAMP, was targeted to LAMP-containing organelles, which also co-localized with
MHC-class-II-rich intracellular compartments [25]. The immunofluorescence microscopy
study of our plasmid expressing the YF pM/M-E in-frame with LAMP (pL/YFE) produced
findings similar to those of previous studies and suggests that the presence of LAMP was in-
deed able to lead the chimeric protein to lysosomes; in contrast, the expression of pM/M-E
without LAMP (p/YFE) resulted in a reticular membrane distribution. We also investigated the
Table 4. Position and restriction of the YF envelope epitopes in YF-17DD-immunized BALB/c (H2d) mice.
YF envelope peptide position Peptide sequence Restriction
E25-39 LEQDKCVTVMAPDKP CD4
E57-71 RKVCYNAVLTHVKIN CD81/CD4
E61-75 YNAVLTHVKINDKCP CD81/CD4
E129-143 EVDQTKIQYVIRAQL CD42
E133-147 TKIQYVIRAQLHVGA CD42
E157-171 KTLKFDALSGSQEVE CD4
E201-215 ESWIVDRQWAQDLTL CD4
E213-227 LTLPWQSGSGGVWRE CD4
E221-235 SGGVWREMHHLVEFE CD4
E233-247 EFEPPHAATIRVLAL CD4
E237-251 PHAATIRVLALGNQE CD4
E329-343 PCRIPVIVADDLTAA CD8
E425-439 GFFTSVGKGIHTVFG CD4
E437-451 VFGSAFQGLFGGLNW CD4
E461-475 LIWVGINTRNMTMSM CD4
E465-479 GINTRNMTMSMSMIL CD4
E473-487 MSMSMILVGVIMMFL CD4
E477-491 MILVGVIMMFLSLGV CD4
1 These peptides contained class I immunodominant epitopes and secondary class II epitopes.
2 These peptides contained class II immunodominant epitopes (Maciel et al., 2008).
doi:10.1371/journal.pntd.0003693.t004
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immunogenicity of these two plasmids as DNA vaccines against YF virus infection. The perfor-
mance of our DNA constructs was compared with the successful human YF 17DD vaccine,
which is a better positive control than the inactivated virus emulsified in CFA, for example [17,
22], which is used when an approved vaccine is not available.
We first carried out epitope mapping of the E protein, comparing the 17DD vaccine with
the p/YFE and pL/YFE DNA constructs. We observed that the epitope profile repertoire
Fig 4. Kinetics of the neutralizing antibody levels in C57Bl/6 and BALB/c mice.C57Bl/6 and BALB/c mice were immunized with the YF 17DD vaccine,
the DNA constructs or PBS on days 0, 30 and 45, and sera were obtained on days 15, 45 and 60. Sera were tested individually in neutralization assays and
compared with a standard monkey serum having a known concentration of anti-YF neutralizing antibodies. The figures represent 1 of 3 experiments, which
each had similar results. Bars represent the mean ± SE of 3–14 mice/group.
doi:10.1371/journal.pntd.0003693.g004
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recognized by the T cells of mice immunized with the DNA constructs was very similar to that
of mice immunized with the standard YF vaccine. Moreover, the majority of the T-cell re-
sponses in the DNA-immunized mice showed higher numbers of IFN-gamma SFCs compared
with the numbers observed for the 17DD vaccine. The immunization of C57Bl/6 mice with the
DNA constructs expressing the whole envelope protein resulted in recognition of three extra
peptides that were not produced by the YF 17DD vaccine. The T-cell response against the pep-
tide E169–183 generated by p/YFE and pL/YFE was significant, and the responses to the peptides
E413–427 and E417–431 were even higher in mice immunized with p/YFE compared with mice
immunized with pL/YFE.
It seems that DNA immunization was able to lead to the presentation of some additional
epitopes that are not normally induced by the YF 17DD vaccine. It is possible that different an-
tigen-presenting cells (APCs) processed different epitopes, according to the source of the anti-
gen, i.e., attenuated virus or DNA plasmids. However, the lack of response to the E329–343
15-mer observed in BALB/c mice immunized with DNA seemed to be partially because the
same cells were able to respond to the minimum epitope within that sequence, as seen against
the 9-mer E330–338. Our results also expanded the C57Bl/6 (H2
b) epitope mapping for the enve-
lope protein of the YF virus. Sequences E1–15 and E233–247 were previously described as contain-
ing CD8 and CD4 epitopes, respectively [39]; however, we were able to identify several new
epitopes, six for CD4 and four for CD8 (Table 2).
The presence of anti-YF nAb is a recognized hallmark of protection against YF infection. A
dose of 104 PFUs of YF 17DD virus was potent enough to produce a high concentration of nAb
after a single immunization in both mouse strains. The plasmid expressing the chimeric
E-LAMP protein (pL/YFE) was able to produce significantly higher concentrations of anti-YF
nAb after three immunizations in both mouse strains compared with the controls or p/YFE;
however, the levels of nAb were considerably lower compared with the YF 17DD immuniza-
tion. The p/YFE plasmid, expressing only the YF E protein, failed to generate high levels of
anti-YF nAb in BALB/c mice and produced only a modest increase of anti-YF nAb in C57Bl/6
mice. These data are in accordance with previous reports demonstrating that the expression of
chimeric proteins in-frame with LAMP lead to an improvement in B-cell responses [17, 22,
30]. Others have used extended immunization protocols to produce higher levels of antibody
[17]. Although we have not tested this hypothesis here, it is interesting to speculate that extra
DNA immunizations could further increase the levels of anti-YF nAb observed.
In addition to nAb, complement-fixing antibodies have also been described as a protective
mechanism against YF [40, 41]. In fact, it has been shown in an animal model that expression
of the YF NS1 protein in the vaccinia virus could partially protect mice from an intracranial
Table 5. C57Bl/6 and BALB/c mouse challenge experiments after immunization with the YF 17DD vaccine or the DNA constructs.
Immunization Challenge (105
PFUs)
C57Bl/6 BALB/c
Mortality (deaths/ total
number inoculated)
Average survival time
(days ± SD)
Mortality (deaths/ total
number inoculated)
Average survival time
(days ± SD)
YF 17DD
vaccine
YF 17DD virus 0/10 - 0/10 -
p/YFE YF 17DD virus 0/10 - 0/10 -
pL/YFE YF 17DD virus 0/10 - 0/10 -
Empty vector YF 17DD virus 10/10 12.8±0.92 8/10 10.3±0.46
PBS YF 17DD virus 10/10 12.4±0.97 9/10 10.9±1.17
PBS PBS 0/5 - 0/5 -
doi:10.1371/journal.pntd.0003693.t005
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challenge [42], most likely through a mechanism involving complement-fixing antibodies. We
cannot rule out the hypothesis that immunization with the YF envelope protein, as a DNA
plasmid, could lead to the presentation of B-cell epitopes different from those found after
Fig 5. Survival curves for C57Bl/6 and BALB/c mice after challenge experiments. C57Bl/6 and BALB/c immunized mice were challenged with 105 PFUs
of the YF 17DD virus, administered via intra-cerebral injection. Both mouse strains were completely protected by the 17DD and both DNA-based (p/YFE and
pL/YFE) vaccines. Overall, C57Bl/6 mice were considered more susceptible than BALB/c mice because C57Bl/6 mice in the negative control groups (empty
vector and PBS) began to die 8 days after the challenge and all animals were dead by day 12, whereas the BALB/c mice in the negative control groups began
to die 10 days after the challenge and very few animals were still alive after the challenge experiment.
doi:10.1371/journal.pntd.0003693.g005
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immunization with the attenuated YF vaccine. Moreover, these epitopes could be sites for neu-
tralizing and complement-fixing antibodies. Thus, the characterization of the B-cell epitopes in
the context of DNA vaccines could potentially become a relevant parameter for comparing
DNA vaccines to their virus-attenuated counterparts.
To further explore the protection provided by DNA immunization, we challenged immu-
nized mice with an intracranial injection of the 17DD virus. This in vivo protection assay en-
ables the evaluation of how effectively a vaccine candidate can prevent the encephalitis caused
by infection with the YF virus, and it has been extensively used [35, 41–44]. Both DNA con-
structs, p/YFE and pL/YFE, were able to protect both mouse strains from an intracranial chal-
lenge. These two plasmids were able to promote a very similar profile of T-cell epitope
recognition compared to the YF 17DD vaccine. However, only the pL/YFE was able also to pro-
duce significant levels of anti-YF nAb. It is possible that the p/YFE plasmid, which did not
raise appreciable levels of anti-YF nAb, led to the protection of the challenged mice through
complementary mechanisms in the presence of low levels of nAb. It is also possible that strong
T-cell responses were able to mediate protection in this system. T cells may play a role in pro-
tection from encephalitis caused by flaviviruses; it has been demonstrated that the depletion of
CD4+ and/or CD8+ lymphocytes leads to a decrease in the protection offered by an experimen-
tal vaccine expressing the dengue envelope protein in the context of the YF virus [39]. The pos-
sibility that these DNA vaccines provide T-cell mediated protection is very interesting and we
are planning to investigate this in more detail.
The results reported here are very encouraging, and we are confident that this vaccine can-
didate is worth further investigation in more relevant animal models, specifically in a non-
human primate challenge model. It is interesting that even with lower neutralizing antibody ti-
ters the DNA vaccine was still capable of protection, suggesting an important role for T-cell
mediated protection. In further studies, we plan to dissect in more details the mechanisms of
protection provided by these DNA vaccines. Another critical point is the duration of the pro-
tection, and this also needs to be addressed in more relevant animal models. In summary, this
research shows that expression of the envelope protein in-frame with the cytoplasmic targeting
sequence of LAMP led to high levels of anti-YF nAb and produced a strong T-cell response.
The possibility of generating a protective anti-YF response through a DNA vaccine may pro-
vide a safer alternative to the attenuated YF virus vaccine and should be further investigated.
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